38
Participants
Start Date
May 31, 2014
Primary Completion Date
February 16, 2021
Study Completion Date
March 4, 2021
Stereotactic radiotherapy
SRT to all areas of oligo-progression as follows: BRAIN: 20-24 Gy in 1 fraction if \< 2 cm,18 Gy in 1 fraction if 2-3 cm,15 Gy in 1 fraction for 3-4 cm, alternatively 25-30 Gy in 5 fractions can be used; SPINE: 18-24 Gy in 1-2 fractions,24 Gy in 3 fractions or 30-40 Gy in 5 fractions; NON-SPINE BONE: 30-40 Gy in 5 fractions; LUNG: 48-60 Gy in 4 fractions or 54-60 Gy in 3 fractions for peripheral lung tumours,50 Gy in 5 fractions or 60 Gy in 8 fractions for central lung tumours; LIVER: 30-60 Gy in 3-6 fractions,higher doses for central liver lesions and lower doses for peripheral liver lesions depending on proximity to adjacent organ (stomach, small bowel, large bowel or kidney); ADRENAL OR KIDNEY TUMOURS: 30-40 Gy in 5 fractions; LYMPHADENOPATHY: 30-40 Gy in 5 fractions.
Tom Baker Cancer Centre, Calgary
Cross Cancer Institute, Edmonton
BC Cancer Agency, Vancouver
Manitoba CancerCare Institute, Winnipeg
QEII Health Sciences Centre, Halifax
Juravinski Cancer Centre, Hamilton
London Health Sciences Centre, London
Ottawa Hospital Cancer Centre, Ottawa
Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto
Princess Margaret Hospital, Toronto
McGill University Health Centre, Montreal
Jewish General Hospital, Montreal
Collaborators (1)
Pfizer
INDUSTRY
Sunnybrook Health Sciences Centre
OTHER